Curriculum Vitae

Nicoletta Brega

Current address: Via Volturno 6 - 27100 Pavia – Italy
Mobile : (+39) 3421271403
E mail : nicoletta.brega@bayer.com

Summary of Qualifications

Education

Degrees

2008 - Second Degree: Medicine and surgery - School of Medicine, University of Pavia – Italy

2008 - Medical Licensure

1989 - First degree in Pharmacy University of Pavia – Italy

Postdoctoral training -University of Pavia-Italy/ University of Geneva (CH)
Specialization in Industrial Pharmacy , 1994: ''Conduction and partial results of a double blind multi-center study on the activity and tolerability of a new drug for Parkinson Disease"

Working experience

- Consolidated experience in global clinical development in pharmaceutical industry with more than 15 years of experience in Oncology in both early and late development. Worked on the filing (EU and US) of 2 oncology drugs (SUTENT®– leading the renal indication - and XALKORI®- ALK+ NSCLC) and leading a number of early development projects (HSP90i, CHK1i, RTKi , Brafi , MEKi, PI3K/mTor) :
- International working experience and consolidated experience in managing people abroad-
- Building/consolidating the Italian oncology SME group since I joined Bayer in 2015
- Clinical experience: internship by the ICU of the IRCCs S Matteo Hospital- Pavia - Italy
- Internship by the Oncology unit of the IRCCS S. Matteo Hospital- Pavia and IEO (European Institute of Oncology – Milan)
- Exchange program experience (2006) : Krakow (Poland) Pediatric Hospital
- Calcutta project MSF – Mother and Child Clinic – Calcutta (India) : Support Doctor (2006)
- PhD student by the Dept of Clinical Pharmacology University of Geneva (CH) – (1992)

CURRENT POSITION & RESPONSIBILITIES

Bayer SpA - *Sr. Clinical Leader (CDL)*, Larotrectinib program, Oncology SBU

From Sept 2015 to December 2018: *Head Study Medical Experts*, Oncology SBU

- Managing the Study Medical Experts group in Europe (Italy and Germany) and China within the oncology SBU department; overall 13 people;
- Supporting the Global Clinical Development teams bringing extensive experience on multiple indications and compounds in the TA;
- Ensuring high standard medical support for the study teams and effective resource management;
- Acting as A-line manager for DMs and SLM located in Italy and overseeing the local budget for the whole group;
- Contributing to process and ensure the resources optimization in collaboration with other functions and TA

Pfizer - Oncology BU：*Director Clinical Development Oncology BU* (direct report to the VP Global Early Development Oncology)

From 2014 – to August 2015 CRC *Lead and Global Clinical Lead EDG*

Leading a number of early assets including PI3K/mTor and MEKi

Within this role I was committed to:

- Managing all the accountability for the designated projects (from Phase 1 to proof of concept);
- Providing therapeutic area clinical expertise to the projects assigned;
- Providing specific medical guidance and expertise;
- Leading multifunctional clinical team to design, implement, deliver and report the project studies
- Planning and directing clinical programs (including development plan, writing full development programs) and studies (including protocol preparation; clinical phase oversight);
- Being Responsible for the preparation and defense of NDA/MAA and clinical plans;
- Being Responsible for presenting and defending Clinical Plans to Governance bodies;
- Providing Clinical TA support to Discovery as appropriate;
- Coaching and develop assistant clinicians / clinical scientists;
- Providing therapeutic area clinical expertise to project;
- Managing Clinicians and other personnel assigned to projects under my responsibility.

From 2011 to 2014 *Clinical Lead within the Global Late Development Group* :

Focused on a late development project (Crizotinib/Xalkori®), with responsibility to support FDA and EMA filing for the ALK+ primary indication (ALK +Lung) and leading and developing the plan for other indications (CMET+ lung / solid tumors and ALCL). Developing and discussing the pediatric investigational plan in collaboration with The Children' s Oncology Group (COG), (NCI) National Cancer Institute.

From 2009 to 2011 *Clinical Lead* within the Early Development Group :

Responsible for the development of 3 compounds in early development (HSP90i, CHK1i, RTKi) and acting as clinical counsel to the BRAFi preclinical team.

2004-2008:

Student by the MD School of Medicine, University of Pavia and working as *Associate Director- Clinician* for Pfizer Oncology. I was responsible for:

- The accountability for the designated studies
- The preparation of protocols, CRFs and study reports consistent with program strategy
- Driving and coordinating all relevant components of clinical trials
- Managing the relations with the Market Companies CROs and investigators

2000 – 2004:

Pharmacia Corporation S.p.A. Nerviano *Manager Clinical research Oncology*

RTKs Inhibitors- European program (phase I/II) Sutent European program (Phase I/II/III)

- Responsible for program implementation within the European region Supporting the Clinical Program Director in preparation of Clinical development plan, Investigator Brochure, Abstracts, Posters and Publications
- Leading Sutent Phase 1 and Phase 3 in RCC and leading submission activities in EU
- Owner of protocols acting as study manager of phase I/II exploratory studies in solid cancers, multiple myeloma and AML running in major cancer centers within European Countries and Australia and leading Study Management Teams
- Responsible for preparation of protocols, CRFs and study reports consistent with program strategy
- Drive and coordinates all relevant components of clinical trials
- Management of relations with the Market Companies CROs and investigators

1998 – 2000

Pharmacia Corporation S.p.A.Nerviano *Acting Clinical Research Implementation Manager (Clinical Research Oncology)*

Responsible for:

- Coordination and management of the Clinical Trial Associates (group with 10 CTAs reporting to me)
- CTA representative in the oncology clinical study teams
- Reference person for all study management aspects
- Supervision and support of CTAs daily activities
- Allocation of resources to projects
- Organization of job rotation and training events
- Interaction with the Global Standards Library organization on standard-related issues, ensuring that the available standards are widely adopted across projects
- Member of the Output Reporting Development Team

▪

Farmiltalia Carlo Erba 1993 – 1998

1995-1998

Study Director (Clinical Development Central Nervous System - CNS)

- Worked on Anti-epilepsy and anti-schizophrenia compounds
  - Co-ordination of all activities related to clinical studies
  - Study management and Data management

1993-1995

MRA – Medical Research associate (Clinical Development Central Nervous System - CNS)

- Worked on Anti-Parkinson compound
  - Involved in the preparation of Carbergoline (Cabaser ®) European registration file, data cleaning , preparation of final reports and answers to the H. Authorities questions .

Most relevant Publications / Abstracts

-Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F.
J Thorac Oncol. 2017 Jan;12(1):145-151. doi: 10.1016/j.jtho.2016.09.131. Epub 2016 Sep 30

-Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer.
Tan W, Yamazaki S, Johnson TR, Wang R, O'Gorman MT, Kirkovsky L, Boutros T, Brega NM, Bello A.
Clin Drug Investig. 2017 Apr;37(4):363-373. doi: 10.1007/s40261-016-0490-z.

-The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Xu H, O'Gorman M, Tan W, Brega N, Bello A.
Eur J Clin Pharmacol. 2015 Dec;71(12):1441-9. doi: 10.1007/s00228-015-1945-5. Epub 2015 Sep 18.

-Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Xu H, O'Gorman M, Boutros T, Brega N, Kantaridis C, Tan W, Bello A.

-Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies.
Reddy N, Voorhees PM, Houk BE, Brega N, Hinson JM Jr, Jillela A.
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):385-91. doi: 10.1016/j.clml.2013.03.010. Epub 2013 Jun 10.

-Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies.
Scott AM, Mitchell PL, O'Keefe G, Saunder T, Hicks RJ, Poon A, Baum C, Brega N, McCarthy TJ, Toner GC.
EJNMMI Res. 2012 Jun 9;2(1):31. doi: 10.1186/2191-219X-2-31.

-The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Hu-Lowe D, Brega N, Patyna S.
Mol Cancer Ther. 2011 Nov;10(11):2015. doi: 10.1158/1535-7163.MCT-11-0722. No abstract available.

-A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.
Clin Cancer Res. 2011 Nov 1;17(21):6831-9. doi: 10.1158/1078-0432.CCR-11-0821. Epub 2011 Sep 9.

-Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
De Jonge MJ, Dumez H, Kitzen JJ, Beuselinck B, Verweij J, Courtney R, Battista A, Brega N, Schöffski P.
Eur J Cancer. 2011 Jun;47(9):1328-35. doi: 10.1016/j.ejca.2011.02.012. Epub 2011 Mar 23.

-A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC.
Br J Cancer. 2010 Sep 28;103(7):993-1000. doi: 10.1038/sj.bjc.6605852. Epub 2010 Aug 17.

-Phase I trial of SU14813 in patients with advanced solid malignancies./ASCO 2007 oral
Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky DR, Bokemeyer C, Boven E.
Ann Oncol. 2011 Jan;22(1):195-201. doi: 10.1093/annonc/mdq313. Epub 2010 Jul 6.

-Phase I Clinical Trial of Gemcitabine in Combination with PF-00477736, a Selective Inhibitor of CHK1 Kinase N Brega, G McArthur, CD Britten, SG Wong, E Wang, K Wilner, A Blasina, GK Schwartz, J Gallo, A Tse – ASCO 2010

-- A phase I study of sunitinib in combination with FOLFIRI chemotherapy in treatment-nave, metastatic colorectal cancer- ASCO GI 2007

-Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. / ESMO 2003 Oral
Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E.
J Clin Oncol. 2006 Jan 1;24(1):25-35. Epub 2005 Nov 28.

-A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK.
Blood. 2005 Feb 1;105(3):986-93. Epub 2004 Sep 30.

-A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE.
Blood. 2003 Oct 15;102(8):2763-7. Epub 2003 Jul 3.